Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

Translated title of the contribution: Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

I.H. Bartelink, T. Wolfs, M. Jonker, M. de Waal, A.C.G. Egberts, T.T. Ververs, J.J. Boelens, M.B. Bierings

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Invasive fungal infections are of great concern in pediatric hematopoietic stem cell transplantation (HSCT) recipients. Voriconazole is usually the drug of first choice for treating or preventing invasive aspergillosis. Optimum trough levels (C(trough)s) are between 1 and 5 mg/liter. It is unclear whether these levels are reached with currently advised pediatric dosing schedules. Between 2007 and 2011, 11 patients 12 years) (P = 0.034). The intrapatient variability in C(trough) ranged between 1 and 238%. Voriconazole was discontinued in six patients due to toxicity. These patients had a median C(trough) of 0.5 mg/liter at the initial dose (ranging from 0.5 to 2.6 mg/liter), and a medium maximal concentration of 4 mg/liter was reached. Inter- and intrapatient variability is a major concern in voriconazole treatment and necessitates therapeutic drug monitoring of dosing, especially in young children.
Translated title of the contributionHighly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.
Original languageUndefined/Unknown
Pages (from-to)235-240
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.'. Together they form a unique fingerprint.

Cite this